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Cryptosporidium muris, predominantly a rodent
species of Cryptosporidium, is not normally considered a
human pathogen. Recently, isolated human infections have
been reported from Indonesia, Thailand, France, and
Kenya. We report the first case of C. muris in a human in
the Western Hemisphere. This species may be an emerg-
ing zoonotic pathogen capable of infecting humans.
Cryptosporidiosis can be a debilitating diarrheal dis-ease. While infections are normally acute and self-
limiting in immunocompetent persons, cryptosporidiosis
can be life threatening in those with compromised immune
systems. In humans, cryptosporidiosis is caused predomi-
nantly by Cryptosporidium parvum or C. hominis (the lat-
ter was previously known as the C. parvum human geno-
type), and major outbreaks of the disease have been clear-
ly associated with contaminated drinking water (1). 
Recently, another species of Cryptosporidium, C.
muris, has been suggested to be of concern to human
health. C. muris is a parasite first identified in the gastric
glands of mice (2). Experimental transmission studies have
shown that the parasite readily infects multiple nonrodent
hosts including dogs, rabbits, lambs, and cats (3). C.
muris–like organisms have also been reported as oppor-
tunistic infectious agents in immunocompromised nonhu-
man primates (4). In the past 2 years, five cases of infec-
tions with C. muris or C. muris–like parasites have been
reported from HIV-positive and healthy persons in Kenya
(5), France (6), Thailand (7), and Indonesia (8). In this
paper, we report on the first documented case of C. muris
in a human in the Western Hemisphere. The parasite was
recovered during the summer of 2002 in stools of an HIV-
positive Peruvian woman with severe diarrhea. This find-
ing was confirmed by light microscopy, polymerase chain
reaction (PCR)–restriction fragment length polymorphism
(RFLP), and DNA sequencing. 
The Study
In 2002, we conducted a year-long collaborative study
on the epidemiology of Cyclospora cayetanensis infec-
tions in Perú. As part of that study, we collected approxi-
mately 100 stool samples in 2.5% potassium dichromate
solution from persons in Lima and Iquitos with
Cyclospora infection. Fecal samples were initially identi-
fied as Cyclospora-positive in Lima, and then transported
to the United States for additional confirmation using wet
mount and Nomarski interference contrast microscopy. 
Two stool samples, which were taken on two sequential
days from an HIV-positive woman who was 31 years of
age, contained oocysts that appeared, based on morpholo-
gy, to be Cryptosporidium muris. Low numbers of
Cyclospora cayetanensis and Blastocystis hominis oocysts
were also identified in the stool samples. The
Cryptosporidium muris infection was initially identified
by using wet mount microscopy with oocysts (n=25) aver-
aging 6.1 (± 0.3) x 8.4 (± 0.3) µM (range 5.6–6.4 x
8.0–9.0) and a shape index (length/width) 1.38 (1.25–1.61)
(Figure 1). Numbers of oocysts were determined semi-
quantitatively in each sample by hemacytometer, with an
estimated 737,000 and 510,000 oocysts/g recovered from
the submitted samples on day 1 and day 2, respectively.
The diagnosis of C. muris was later confirmed through
DNA analysis. 
HIV was first diagnosed in the patient in November
2000 by using enzyme-linked immunosorbent assay and
Western blot (immunoblot). She arrived at the hospital
clinic in June 2002 with fever and reported that she had
been experiencing diarrhea for >3 months. The patient
reported that she had lost approximately 25 lbs. in the past
7 months, consistent with HIV-wasting syndrome. Her
chest x-ray was abnormal, but four direct sputum examina-
tions for acid-fast bacteria using Ziehl-Neelsen staining
were negative, as were efforts at culturing Mycobacterium
tuberculosis. 
Other laboratory values for this patient at the time of
stool sample collection were as follows: CD4 cell count
66/µL; hematocrit 36%; leukocytes 4,100/µL with 4%
bands, 55% neutrophils, 27% lymphocytes, and 0%
eosinophils; urine examination normal; creatine 0.8
mg/dL; urea 21 mg/dL; glucose 105 mg/dL; serum glutam-
ic oxalacetic transaminase 30 IU/L; serum glutamic pyru-
vic transaminase 46 IU/L; and bilirubin 0.9 mg/dL. 
The diagnosis of Cryptosporidium in the patient’s sam-
ples was confirmed by a small subunit rRNA-based nested
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PCR, which amplified a portion of the rRNA gene (830
bp).  Cryptosporidium spp. was determined by the banding
patterns of restriction digestions of PCR products with
SspI, VspI, and DdeI (9). Diagnosis was confirmed by
DNA sequencing of three independent PCR products from
each sample in both directions on an ABI PRISM 3100
(Applied Biosystems, Foster City, CA) instrument. Figure
2 shows the RFLP analysis of three PCR products from
each sample with restriction enzymes SspI and VspI; these
results suggest that these PCR products belonged to either
C. muris or Cryptosporidium andersoni (10). Further
RFLP analysis with DdeI showed banding patterns identi-
cal to C. muris (9; Figure 2). All DNA sequences obtained
from the six PCR products were identical to those previ-
ously reported by Xiao et al. (10,11) from C. muris from a
Bactrian camel, a rock hyrax, and mice (GenBank acces-
sion nos. AF093997 and AF093498) and another isolate
recently found in an HIV patient in Kenya (5). 
After the diagnosis of intestinal parasite infection, the
patient was treated with TMP-SMX (trimethoprim 160
mg, sulfamethoxazole 800 mg) Forte twice a day for 1
week and then TMP-SMX once a day for Pneumocystis
carinii pneumonia prophylaxis. The patient was also
placed on AZT/3TC and nevirapine. The patient recovered
with no further evidence of Cyclospora, Blastocystis, or C.
muris in stool samples taken 2 months posttreatment. She
became afebrile and had gained 5 kg as of 2 months’ post-
treatment. Molecular analysis of a stool sample collected
122 days after the initial diagnosis confirmed that the
patient had recovered from the C. muris infection.
Conclusions
This report represents the third confirmed case of C.
muris infection in humans. Previously, one case of C.
muris infection was identified in an HIV-positive child in
Thailand and in an HIV-positive adult in Kenya using
microscopy and molecular analysis (5,7). C. muris and C.
andersoni–like oocysts were found in two healthy
Indonesian girls, but the diagnosis was not confirmed by
molecular tools (8). One putative C. muris infection was
reported in an immunocompromised patient in France
based on sequence analysis of a small fragment of the SSU
rRNA (6). However, the sequence presented was more
similar to that of C. andersoni (2-bp differences in a 242-
bp region) than to C. muris (8-bp differences in the
region).
Although determining whether or not the C. muris con-
tributed medical problems in this patient is not possible,
detecting C. muris in her stool sample is an unexpected
finding. A major difference between C. parvum or C.
hominis and C. muris, is that C. parvum and C. hominis
normally colonize the intestine, whereas C. muris is a gas-
tric pathogen in cattle. Anderson (12) and Esteban and
Anderson (13) reported that another gastric species, C.
andersoni, infects only the glands of the cattle stomach
(abomasum), where it retards acid production. These
researchers postulated that this process may affect protein
digestion in the abomasum and account for the fact that
milk production in cows that are chronically infected with
C. muris appears to be reduced by approximately 13%.
Thus, an infection by C. muris may perhaps cause similar
protein digestion problems in human infections, particular-
ly in HIV-positive persons. 
Even though only a few cases of C. muris infections
have been identified so far in humans, gastric cryp-
tosporidiosis occurs much more often than believed, espe-
cially in HIV-positive persons. Up to 40 % of cryp-
tosporidiosis in HIV-infected persons includes gastric
involvement (14). Although most gastric Cryptosporidium
infections in HIV-positive persons are likely caused by C.
parvum or C. hominis because of immunosuppression, the
contribution of C. muris probably has been underestimat-
ed. Thus, molecular characterizations of stomach tissues
from patients with gastric cryptosporidiosis may help us to
understand the pathogenesis of human Cryptosporidium
infection.
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Figure 1. Nomarski interference contrast photomicrographs of
Cryptosporidium muris from the feces of an HIV-positive human.
Scale bars = 5 µm.
Figure 2. Identification of Cryptosporidium muris from two stool
samples from a Peruvian patient using restriction fragment length
polymorphism analysis of polymerase chain reaction products with
SspI (A), VspI (B) and DdeI (C). Lane 1, 100-bp molecular mark-
ers; lane 2, C. hominis control; lanes 3 and 4, C. muris from the
patient.
Our report expands the geographic range of suspect C.
muris infections in humans and suggests that this species
may be a global emerging zoonotic pathogen. This
pathogen may be of particular importance to persons living
in regions where rodents live in close proximity to humans
and sanitation may be minimal. C. muris may also be more
prevalent than currently recognized. The organism is near-
ly twice as large as C. parvum and closer in size to
Cyclospora cayetanensis. Although Cyclospora autofluo-
resces while Cryptosporidium does not (15), C. muris could
still be easily misdiagnosed, since few laboratory workers
would be familiar with C. muris or its morphology. 
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